Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration‐resistant prostate cancer

Elevated serum chromogranin A (CGA) is associated with intrinsic or treatment‐related neuroendocrine differentiation (NED) in men with metastatic castration‐resistant prostate cancer (mCRPC). Fluctuations in serum CGA during treatment of mCRPC have had conflicting results. We analyzed the impact of (i) rising serum CGA and (ii) baseline CGA/PSA ratio during treatment to identify associations with abiraterone acetate (AA) therapy.

• Publication year

  2023

• Venue

  The Prostate

• Publication date

  2023-03-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pros.24498PMID 36924119PMCID PMC11537207
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comprehensive analysis of serum chromogranin A and neuron‐specific enolase levels in localized and castration‐resistant prostate cancer

  2020influential reference
• Plasma androgen receptor and serum chromogranin A in advanced prostate cancer

  2018cited by this paper
• Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.

  2018cited by this paper
• Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer

  2018cited by this paper
• Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy‐naive metastatic castration‐resistant prostate cancer

  2017influential reference
• Mechanisms of Therapeutic Resistance in Prostate Cancer

  2017cited by this paper
• Chromogranin A and neurone‐specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration‐resistant prostate cancer

  2017influential reference
• Chromogranin A as a valid marker in oncology: Clinical application or false hopes?

  2017cited by this paper
• Chromogranin A and neurone‐specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration‐resistant prostate cancer undergoing abiraterone therapy

  2017cited by this paper
• Influence of abiraterone acetate on circulating neuromediators in chemotherapy‐naïve castration‐resistant prostate cancer

  2016cited by this paper
• Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals

  2015cited by this paper
• Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide

  2014cited by this paper
• Aggressive Variants of Castration-Resistant Prostate Cancer

  2014influential reference
• The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression

  2014influential reference
• Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.

  2014cited by this paper
• High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development.

  2014cited by this paper
• Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.

  2013cited by this paper
• Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours

  2011cited by this paper
• Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.

  2007cited by this paper
• Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.

  2007cited by this paper
• Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.

  2006cited by this paper
• REporting recommendations for tumour MARKer prognostic studies (REMARK).

  2005cited by this paper
• Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma.

  2005cited by this paper
• Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells.

  2003cited by this paper
• Use of neuroendocrine serum markers in the follow‐up of patients with cancer of the prostate

  1997cited by this paper

• Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysis

  2025cites this paper